HC Wainwright Issues Positive Outlook for MLYS Earnings

Key Points

• HC Wainwright raised its MLYS earnings forecasts, estimating a third-quarter 2026 loss of $0.54 per share versus its previous $0.56 estimate and maintaining a “Buy” rating. It projects the company will turn profitable in 2029, reaching $4.13 per share in earnings by 2030.
• Mineralys Therapeutics reported a quarterly loss of $2.85 per share, missing the $0.55 consensus estimate by $2.30. Analyst sentiment remains mixed, with the stock carrying a consensus “Hold” rating and an average price target of $49.33.
• MLYS shares opened at $25.65, well below their 12-month high of $47.65, while institutional investors own 84.46% of the company. Insiders sold 216,896 shares worth approximately $5.6 million during the latest quarter.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Research analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of Mineralys Therapeutics in a research report issued on Thursday, August 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.54) per share for the quarter, up from their prior estimate of ($0.56). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Mineralys Therapeutics' Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($4.40) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at $1.12 EPS and FY2030 earnings at $4.13 EPS.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.30).

A number of other brokerages also recently weighed in on MLYS. Zacks Research downgraded Mineralys Therapeutics from a "hold" rating to a "strong sell" rating in a report on Thursday, August 13th. TD Cowen initiated coverage on Mineralys Therapeutics in a research report on Monday, April 27th. They set a "buy" rating on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Finally, Jefferies Financial Group reissued a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Mineralys Therapeutics presently has a consensus rating of "Hold" and an average target price of $49.33.

Mineralys Therapeutics Price Performance

MLYS stock opened at $25.65 on Monday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -6.05 and a beta of 0.68. The company has a quick ratio of 34.46, a current ratio of 34.46 and a debt-to-equity ratio of 0.18. Mineralys Therapeutics has a 12-month low of $14.53 and a 12-month high of $47.65. The company's fifty day simple moving average is $26.74 and its 200 day simple moving average is $27.30.

Institutional Investors Weigh In On Mineralys Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Timothy G. Youngquist 2020 Irrevocable Trust bought a new stake in Mineralys Therapeutics during the second quarter worth $2,721,000. Jennison Associates LLC lifted its stake in Mineralys Therapeutics by 234.4% during the 4th quarter. Jennison Associates LLC now owns 1,258,653 shares of the company's stock valued at $45,677,000 after acquiring an additional 882,307 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in Mineralys Therapeutics during the 4th quarter valued at $13,794,000. Bank of America Corp DE boosted its holdings in Mineralys Therapeutics by 11.5% during the 1st quarter. Bank of America Corp DE now owns 1,100,372 shares of the company's stock worth $29,809,000 after acquiring an additional 113,092 shares during the last quarter. Finally, Artia Global Partners LP boosted its holdings in Mineralys Therapeutics by 143.5% during the 4th quarter. Artia Global Partners LP now owns 137,800 shares of the company's stock worth $5,001,000 after acquiring an additional 81,200 shares during the last quarter. Institutional investors own 84.46% of the company's stock.

Insider Activity at Mineralys Therapeutics

In related news, Director Daphne Karydas sold 3,000 shares of the business's stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the sale, the director directly owned 6,200 shares of the company's stock, valued at $155,000. The trade was a 32.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 9,890 shares of the company's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.81, for a total value of $235,480.90. Following the transaction, the insider directly owned 57,095 shares in the company, valued at approximately $1,359,431.95. This trade represents a 14.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 216,896 shares of company stock worth $5,613,000 over the last quarter. Company insiders own 18.94% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source